Dragonfly's TriNKET compounds are designed to activate and direct NK and cytotoxic T cell killing against cancer cells. The platform has also attracted partnerships from other pharma groups ...

ImmunityBio has announced the commencement of a Phase I clinical trial evaluating its CD19 targeted high-affinity natural ...

NK cells have been shown to play a pivotal role in HCC, with multiple trials underway assessing the effectiveness of NK cell–based treatment in the cancer type, which carries a poor prognosis ...